TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07005180: Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Sponsor: Hillhurst Biopharmaceuticals, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,474,400

Rescue Site Savings

+$970,000

Unlock Full NCT07005180 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07005180 Rescue Dossier →